Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $9.26B | $8.54B | +8.33% |
Cost of Revenue | $2.72B | $2.56B | +6.17% |
Net Income | $2.49B | $2.34B | +6.06% |
EPS (Basic) | $5.47 | $5.08 | +7.68% |
EPS (Diluted) | $5.47 | $5.07 | +7.89% |
SG&A Expense | $2.32B | $2.15B | +7.76% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $14.24B | $14.29B | -0.34% |
Current Assets | $5.99B | $6.34B | -5.63% |
Total Liabilities | $9.47B | $9.29B | +1.85% |
Current Liabilities | $3.41B | $1.89B | +80.62% |
Stockholders' Equity | $4.77B | $5B | -4.54% |
Long-Term Debt | $5.22B | $6.56B | -20.48% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.95B | $2.35B | +25.50% |
Investing Cash Flow | $-315M | $-777M | +59.46% |
Financing Cash Flow | $-2.66B | $-3.11B | +14.44% |
Share Buybacks | $1.86B | $1.09B | +70.15% |
D&A | $497M | $491M | +1.22% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 26.9% | — | — |
ROE | 52.1% | — | — |
ROA | 17.5% | — | — |
Current Ratio | $1.754 | — | — |
Debt to Equity | $1.985 | — | — |
Other companies in Pharmaceuticals